ADAG
Adagene Inc. NASDAQ Listed Feb 9, 2021$4.78
+13.81%
vs $4.20
Mkt Cap $180.5M
52w Low $1.41
100.0% of range
52w High $4.78
50d MA $3.72
200d MA $2.79
P/E (TTM)
-3.4x
EV/EBITDA
—
P/B
5.1x
Debt/Equity
0.2x
ROE
-49.8%
P/FCF
-11.5x
RSI (14)
82.30
ATR (14)
$0.45
Beta
0.59
50d MA
$3.72
200d MA
$2.79
Avg Volume
262.4K
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Building C14 · Suzhou, F4 215123 · CN
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | AMC | -0.28 | -0.07 | +75.0% | 4.61 | -14.3% | -13.4% | +8.3% | +2.5% | -9.7% | -3.8% | — |
| Mar 24, 2025 | AMC | -0.33 | -0.55 | -67.7% | 1.77 | -1.1% | -7.3% | +2.4% | -0.6% | -6.6% | -2.6% | — |
| Jul 25, 2024 | AMC | -0.41 | -0.19 | +53.0% | 2.53 | -0.4% | -0.4% | -7.1% | -3.8% | +13.8% | +1.2% | — |
| Mar 31, 2024 | AMC | — | -0.19 | — | — | — | — | — | — | — | — | — |
| Mar 29, 2024 | AMC | -0.42 | -0.17 | +59.8% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.17 | — | — | — | — | — | — | — | — | — |
| Aug 31, 2023 | AMC | -0.38 | -0.05 | +87.6% | 1.36 | -4.4% | +1.5% | -4.3% | +2.7% | +3.3% | +3.6% | — |
| Mar 31, 2023 | AMC | — | -0.05 | — | 1.45 | -3.4% | -6.9% | +1.5% | -0.7% | +8.8% | -4.4% | — |
| Mar 28, 2023 | AMC | -0.40 | -1.55 | -287.5% | 1.45 | +0.0% | +4.1% | -4.0% | +0.0% | -6.9% | +1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Guggenheim | Maintains | Buy → Buy | — | $3.99 | $4.17 | +4.5% | +8.3% | +2.5% | -9.7% | -3.8% | -1.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.01 | $2.05 | +2.0% | -15.9% | +16.0% | +0.0% | +5.6% | +10.1% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.64 | $1.51 | -7.9% | +0.0% | -3.7% | -2.5% | -5.8% | -3.4% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.93 | $2.09 | +8.3% | -4.1% | +1.1% | -1.1% | +0.0% | +2.7% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.33 | $2.41 | +3.4% | -9.0% | +6.1% | +6.7% | -6.2% | -0.9% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.51 | $2.54 | +1.2% | +4.8% | -0.4% | +4.6% | -7.7% | -0.4% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.09 | $2.97 | -3.9% | -1.0% | -0.3% | -2.0% | -3.0% | -2.4% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.51 | $1.55 | +2.6% | -0.7% | -6.0% | +18.1% | +9.9% | -19.7% |
| Sep 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.36 | $1.30 | -4.4% | +1.5% | -4.3% | +2.7% | +3.3% | +3.6% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.48 | $1.51 | +2.3% | -4.7% | -1.4% | -6.5% | +4.2% | -4.8% |
| Mar 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.45 | $1.45 | +0.0% | +4.1% | -4.0% | +0.0% | -6.9% | +1.5% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.55 | $1.58 | +1.7% | -0.2% | -0.9% | -1.1% | -1.3% | -8.7% |
| Jan 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1.84 | $1.75 | -4.9% | +0.0% | +1.6% | +2.9% | +1.3% | -3.6% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.11 | $1.12 | +0.9% | -2.7% | +4.2% | +20.0% | -3.0% | +3.8% |
| Sep 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1.51 | $1.48 | -2.3% | +4.3% | +0.0% | -4.4% | -1.3% | -4.7% |
| Feb 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.24 | $7.20 | -0.6% | +1.1% | +0.5% | -1.6% | -3.3% | +0.0% |
| Jan 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.73 | $7.70 | -0.4% | +5.4% | +7.8% | -1.1% | -4.5% | +5.5% |
| Jul 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $17.70 | $17.45 | -1.4% | +5.2% | +0.1% | +1.9% | +4.6% | +4.0% |
| Jun 25 | China Renaissance | Maintains | Buy → Buy | — | $13.99 | $14.44 | +3.2% | +1.9% | +0.3% | -2.3% | -2.9% | +2.5% |
| Mar 8 | Jefferies | Maintains | Buy → Buy | — | $23.11 | $23.50 | +1.7% | -6.0% | -2.3% | -1.0% | +1.8% | +3.9% |
| Mar 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $23.11 | $23.50 | +1.7% | -6.0% | -2.3% | -1.0% | +1.8% | +3.9% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 17
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Mill Creek Capital Advisors, Llc | 199,610 | $782K | — | Mar 2026 |
| 2 | Morgan Stanley | 151,290 | $286K | Reduced | Dec 2025 |
| 3 | Invesco Ltd. | 47,124 | $185K | New | Mar 2026 |
| 4 | Kamunting Street Capital Management, L.p. | 38,070 | $149K | Reduced | Mar 2026 |
| 5 | Persistent Asset Partners Ltd | 35,126 | $138K | New | Mar 2026 |
| 6 | Dauntless Investment Group, Llc | 34,775 | $136K | New | Mar 2026 |
| 7 | Renaissance Technologies Llc | 34,533 | $135K | New | Mar 2026 |
| 8 | Alyeska Investment Group, L.p. | 20,710 | $81K | New | Mar 2026 |
| 9 | Royal Bank Of Canada | 16,850 | $66K | — | Mar 2026 |
| 10 | Nomura Holdings Inc | 14,710 | $58K | Reduced | Mar 2026 |
| 11 | Quadrature Capital Ltd | 11,617 | $46K | New | Mar 2026 |
| 12 | Eversource Wealth Advisors, Llc | 2,708 | $16K | Reduced | Mar 2026 |
| 13 | Ubs Group Ag | 4,002 | $16K | Added | Mar 2026 |
| 14 | Bnp Paribas Financial Markets | 3,700 | $15K | Added | Mar 2026 |
| 15 | Jpmorgan Chase & Co | 712 | $3K | New | Mar 2026 |
| 16 | Barclays Plc | 400 | $2K | New | Mar 2026 |
| 17 | Northwestern Mutual Wealth Management Co | 12 | $23 | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index Fund | 10,309 | $31K | Feb 2026 |
Valuation
Market Cap
$180.5M
Enterprise Value
$107.1M
P/E (TTM)
-3.37x
Forward P/E
—
PEG Ratio
0.08x
P/B
5.11x
P/S
23.15x
P/FCF
-11.52x
EV/EBITDA
—
Shares Out
37.8M
Financials (TTM)
Revenue
$7.8M
Net Income
-$51.1M
EBITDA
-$52.6M
Free Cash Flow
-$15.7M
Op Cash Flow
-$15.7M
EPS Basic
$-0.46
EPS Diluted
$-1.42
EPS Forward
$-0.48
Gross Margin
74.1%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$78.3M
Total Liab.
$42.9M
Total Equity
$35.3M
Cash
$74.5M
LT Debt
$1.1M
Book Value/Sh
$0.94
Debt/Equity
0.18x
Current Ratio
3.07
Quick Ratio
3.07
Returns & Growth
ROE
-49.8%
ROA
-22.5%
ROIC
-36.2%
Rev Growth YoY
+7332.8%
EPS Growth YoY
+51.3%
Price Returns
2W
+15.4%
1M
+11.1%
3M
-8.9%
6M
+128.3%
12M
+127.0%
Technicals
52W High
$4.78
52W Low
$1.41
50d MA
$3.72
200d MA
$2.79
RSI (14)
82.30
ATR (14)
$0.45
Beta
0.59
Avg Volume
262K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.00
High
$5.00
Low
$5.00
Median
$5.00
Data updated apr 26, 2026 9:26am
· Source: financialmodelingprep.com